Supreme Court Expansion of eminent domain–Sandra Day O’Connor smelled the rat Sat, 2 Jul 2005 In a 5 to 4 decision, Supreme Court Justices John Paul Stevens, David H. Souter, Ruth Bader Ginsburg and Stephen G. Breyer, as well as Reagan appointee Justice Anthony Kennedy, voted to expand the government’s…
FDA Scientist Won’t Present New Pain Drug Data – FDA to Create Independent Drug Safety Board Tue, 15 Feb 2005 A culture of intimidation prevents FDA safety officers from disclosing important safety information about widely marketed drugs. Reuters reports: “Criticism of how the FDA monitors the after-market safety of drugs…
Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Sun, 11 Dec 2005 Two major cases of medical research fraud on each side of the Atlantic involve evidence of fraud and data tampering by pharmaceutical company giants. Both cases provide insight into the way in…
Suicide Rate Unchanged in 10 Years–JAMA / AMA Considers Stand Against Warning Labels on Antidepressants Thu, 9 Jun 2005 A major report in the Journal of the American Medical Association shatters all claims about the effectiveness of antidepressants as a treatment for the prevention of suicide. A comparison of the…
Hearing on Antidepressants Canceled – Washington Post Wed, 21 Jul 2004 The Washington Post confirms AHRP’s assessment about the real reason for the derailment of a much awaited congressional hearing at which the giants of the pharmaceutical industry were to testify: “A Democratic staff member who spoke on the condition…
Member of UK Parliament Accuses Drugs Giant of ‘Voodoo Medicine’ – Scotsman Wed, 25 Feb 2004 Paul Flynn, Member of UK Parliament raised the antidepressant drug scandal in Parliament, focusing on the British drug manufacturer giant, GlaxoSmithKline (GSK). “The Seroxat [Paxil] scandal is one of gigantic proportions that affects millions…
FDA’s Lethal Weakness Requires More than Committees Sun, 7 Nov 2004 Bloomberg News reports that New York State Attorney General Eliot Spitzer requested information from Pfizer about the promotion of some of its drugs for unapproved uses – the recalled diabetes drug, Rezulin and the antidepressant, Zoloft were named. In…
Conflicts of Interest policy – New York Times Sun, 28 Mar 2004 To: ‘Executive-editor@nytimes’; ‘gcollins@nytimes’; ‘arosenthal@nytimes’; ‘pboffey@nytimes’; ‘lchang@nytimes’; ‘oped@nytimes’ Cc: ‘Daniel Okrent’ ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Promoting openness and full disclosure https://ahrp.org FYI Friday’s New York Times included the following Editor’s Note on the paper’s Op Ed page:…
APA Under the Influence of PhaRma June 5, 2002 FYI Reporters who attended the 2002 annual convention of the American Association of Psychiatry / PhaRma have had a rude awakening about the scope of industry’s influence. Essentially, psychiatrists are drug marketers for industry, helping to create blockbuster sales: Even…
Next Phase in Psychiatry? Or, NIMH Effort to Rescue Bad Drugs – WSJ Fri, 29 Jul 2005 The Wall Street Journal uncritically reported: “The results of the largest studies ever conducted of depression and schizophrenia will be released in coming months, potentially transforming the way patients are treated and shaking…
Did Zoloft make him do it? FDA Zoloft data Tue, 8 Feb 2005 At issue beyond a Charlsteon, SC court, is whether Christopher Pittman – who was 12 years old and under the influence of Zoloft, a powerful psychotropic drug, when he killed his grandparents–should have been charged with murder…
AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising Wed, 02 Nov 2005 FDA is holding public hearings (Nov 1, 2) Re: Direct-to-Consumer Promotion of Medical Products at: National Transportation Safety Board Boardroom and Conference Center 429 L’Enfant Plaza, SW., Washington, DC 2 Time: 9:00 –5:00….
